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2140Effects of Imiquimod on Hair Follicle Stem
Cells and Hair Cycle Progression
Nicole Amberg1, Martin Holcmann1, Gabriel Stulnig1 and Maria Sibilia1Topical imiquimod (IMQ) application is widely used as a model for psoriasiform-like skin inflammation in
mice. Although the effects on the epidermis are well characterized, it is unclear how IMQ affects hair follicles
and cycling. Here we investigated how IMQ affects hair follicle stem cells and whether the timing of IMQ
application influences the immune infiltrate. Our results show that IMQ application at mid and late telogen
activated hair follicle stem cells leading to premature hair cycle entry (anagen), which was accompanied by
massive infiltration of inflammatory macrophages and gamma delta T cells, whereas the number of the
respective resident populations decreased. Interestingly, high resident macrophage numbers were present in
Rag2/ mice and were maintained after IMQ treatment explaining why IMQ-induced anagen was reduced.
This could be rescued after macrophage depletion suggesting that resident macrophages inhibit whereas
inflammatory infiltrating macrophages stimulate hair follicle stem cell activation. The expression of the
anagen-inhibiting factor BMP-4 was reduced by IMQ treatment as well as the activating factors Wnt showing
that IMQ-induced hair follicle stem cell activation occurs by a Wnt-independent mechanism involving in-
flammatory cytokines such as CCL2 and TNF-a. On the basis of our findings, we recommend conducting
experiments with IMQ during mid and late telogen as the biggest differences in immune cell composition
are observed.
Journal of Investigative Dermatology (2016) 136, 2140e2149; doi:10.1016/j.jid.2016.06.613INTRODUCTION
Imiquimod (IMQ) is a synthetic immune-response modifier
acting as a toll-like receptor 7/8 agonist (Hemmi et al.,
2002). In humans, the 5% IMQ cream formulation
Aldara is frequently used for the treatment of genital warts,
actinic keratosis, and superficial basal cell carcinomas
with very high response rates (Bath-Hextall et al., 2014; de
Macedo et al., 2015; Gollnick et al., 2005; Peris et al.,
2014). In mice and humans, topical application of IMQ
results in the activation of the interfollicular epidermis
(IFE), upregulation of major histocompatibility complex-II
(MHC-II) on keratinocytes, hyperproliferation, and para-
keratosis (Flutter and Nestle, 2013), as well as a strong
skin inflammation characterized by the infiltration of
several immune cells such as plasmacytoid dendritic cells
(Drobits et al., 2012; Kalb et al., 2012; Palamara et al.,
2004), mast cells (Heib et al., 2007), monocytes
(Terhorst et al., 2015), and T cells and activation of the IL-
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an open access art2014; van der Fits et al., 2009). Langerhans cells (LCs) and
gamma delta T cells (gd T cells) are activated in response
to IMQ, leading to emigration of LCs (Flacher et al., 2014;
Palamara et al., 2004; Pantelyushin et al., 2012). In the
past few years, IMQ has been widely used by several re-
searchers as a model for psoriasiform-like skin inflamma-
tion (Perera et al., 2014; Schonthaler et al., 2013; Tortola
et al., 2012; van der Fits et al., 2009), as, similar to
psoriasis, epidermal thickening is induced by IL-22
released from infiltrating immune cells (Van Belle et al.,
2012).
Despite IMQ’s known effects on the IFE, its effects on hair
follicle (HF) and hair follicle stem cells (HFSCs) are un-
known. The HF is a highly organized structure and is sub-
divided into the infundibulum (IF)/junctional zone at the top,
the isthmus, the bulge (Bu), and the lowest part, the sec-
ondary hair germ (2HG) (Amberg et al., 2015; Arwert et al.,
2012; Jaks et al., 2010). Each of these regions of the HF
harbors defined stem cells, which under homeostatic con-
ditions serve to renew their compartment. Following HF
morphogenesis after birth, renewal of the HF occurs in a
largely synchronized manner (hair cycle) in the mouse until
90 days after birth and is divided into three stages, the resting
phase (telogen), active phase (anagen), and destructive phase
(catagen). Toward the end of telogen, quiescent stem cells
from the 2HG and later from the whole Bu become acti-
vated and proliferate to initiate anagen to generate new hair
(Blanpain and Fuchs, 2009; Fuchs, 2007). At the end of
anagen, progenitor cells and transit-amplifying cells stop
proliferating and undergo apoptosis (catagen), leading to HF
shortening and entrance into the quiescent telogen phase
(Greco et al., 2009; Ito et al., 2004; Mesa et al., 2015;
Tumbar et al., 2004).s. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is
icle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Imiquimod (IMQ) treatment during late telogen induces hair follicle stem cell activation. (a) Representative images of hematoxylin and eosin
(H&E) stainings of back skin sections from mice treated with or without IMQ at indicated time points. Black arrows indicate the infundibulum (IF). Scale bar:
100 mm. Quantification of (b) the thickness of the interfollicular epidermis (IFE) and (c) the length of the IF at indicated time points and treatments.
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Effects of Imiquimod on Hair Follicle Stem CellsHFSC activity is highly controlled, not only by stem
cell-derived factors, which can be either inhibitory or
activating, but also by immune cell- or other dermal cell-
derived factors, such as Bmp2, Bmp4, Wnt10, Dkk1, folli-
statin, noggin, Sfrp4, and TNFa (Botchkarev, 2001;
Castellana et al., 2014; Chen et al., 2014, 2015; Plikus
et al., 2008). Because IMQ leads to infiltration of different
immune cell populations into the skin, it is very likely that
they affect HFSC and hair cycle progression. Recently, it
was shown that HF cells are responsive to immune cells,
such as macrophages, which under steady-state conditions
produce factors either inhibiting (e.g., Bmp4) or activating
(e.g., Wnts) HFSCs, depending on the telogen stage
(Castellana et al., 2014). Upon depletion of skin-resident
macrophages by clodronate-mediated apoptosis, the acti-
vating factors were released and HFs entered anagen. Also
dendritic epidermal T cells (DETC) and dermal mast cells
were shown to be present at different concentrations during
the distinct hair cycle stages, emphasizing that there is
crosstalk between HFs and immune cells (Maurer et al.,
1995, 1997; Paus et al., 1994).
In this study, we aimed at investigating the effects of IMQ
on HF and whether IMQ-induced immune responses are
affected during the different hair cycle stages. Because IMQ is
a widely used model of skin inflammation to study psoriasis-
like skin diseases, these parameters are important to consider
when planning experiments with IMQ to guarantee and in-
crease reproducibility and avoiding variances between
different laboratories.RESULTS
IMQ treatment during late telogen induces HF stem cell
activation and premature hair cycle entry
Experiments with topical IMQ are usually performed with 6-
to 12-week-old mice when the second and third hair cycle
occur. We therefore investigated whether IMQ application
results in different effects on the skin when applied at
different stages of the hair cycle. Wild-type C57BL/6 mice
were shaved on the dorsum and 1 day later topically treated
with Aldara for 7 consecutive days starting either at postnatal
day 50 (P50) (early telogen), at P57 (mid telogen), at P65 (late
telogen), or at P80 (anagen) (see Supplementary Figure S1a
online). All IMQ-treated mice responded to treatment irre-
spective of the hair cycle stage, as indicated by the increase
in spleen size, which results from a systemic inflammatory
response that is typically observed in mice after Aldara
treatment (see Supplementary Figure S1b) (Palamara et al.,
2004). IFE thickness and IF length (taken as a readout for
skin inflammation) were increased to various degrees by IMQ
treatment during the different hair cycle stages (Figure 1aec).
The increase in IFE diameter was lowest in mice receiving
IMQ treatment in late telogen, whereas it was comparable
during early telogen and anagen (Figure 1b). IF length already
revealed differences in untreated mice and was significantly
increased in anagen when compared with the other stages
(Figure 1c).
We next analyzed whether IMQ also activates 2HG
and HF Bu stem cells by performing immunofluorescence
staining for the epidermal-dermal boundary marker b4www.jidonline.org 2141
Figure 2. Imiquimod (IMQ) application induces proliferation in distinct epidermal compartments. (a, b) Stainings of back skin sections from mice of indicated
treatment and time points. (a) b4 integrin (A488, green), PSer10H3 (A594, red), nuclei (Hoechst, blue). The white arrows point at PSer10H3þ nuclei in different
epidermal compartments, and the white ellipse indicates dermal papilla (DP). Bu, bulge; 2HG, secondary hair germ; IF, infundibulum; IFE, interfollicular
epidermis; SG, sebaceous gland. Scale bar: 100 mm. (b) Lrig1 (red), PSer10H3 (green), nuclei (blue). The white arrows point at PSer10H3þ nuclei. Scale bar: 100
mm. (cee) Quantification of numbers of PSer10H3þ cells in (c) Bu/2HG, (d) IFE, and (e) IF at indicated time points and treatments. FACS analysis showing the
percentages of Ki67þ cells in (f) integrin a6þ CD34þ bulge cells, (g) Sca-Iþ IFE cells, and (h) Lrig1þ IF cells.
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2142integrin together with the M-phase marker PSer10H3
(Figure 2a). These cells are usually quiescent during telogen
and are therefore PSer10H3-negative. IMQ treatment during
early telogen had no effect on HFSC activation, because we
did not observe PSer10H3þ cells in the 2HG or Bu
(Figure 2a and c). Interestingly, IMQ treatment during mid
and late telogen revealed a profound increase in PSer10H3þ
cells in the 2HG and Bu, leading to identification of pre-
mature anagen entry in up to 90% of all HFs investigated
(Figure 2a and c). We also determined the number of cells in
mitosis in IFE and IF, by counting PSer10H3þ cells either in
the b4 integrinþ fraction of the epidermis (Figure 2a) or in theJournal of Investigative Dermatology (2016), Volume 136Lrig1þ fraction that labels the IF (Figure 2b, see
Supplementary Figure S1c). IMQ treatment during early tel-
ogen increased proliferation of keratinocytes in the IFE and
the IF, but not in the 2HG (Figure 2cee). In contrast, during
mid and late telogen, the proliferation was enhanced in all
three compartments. However, IMQ application during
anagen did not alter proliferation of IFE and IF compared with
untreated mice (Figure 2cee). We were able to confirm these
results by additionally performing Ki67 staining (see
Supplementary Figure S1d), demonstrating precocious HFSC
activation when mice received IMQ treatment during mid
and late telogen (see Supplementary Figure S1e).
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Figure 3. Effects of imiquimod (IMQ) treatment on skin immune cells. FACS analysis of epidermal suspensions isolated from mice treated or not with IMQ at
indicated time points, showing the percentage of (a) MHCIIþ cells, (b) TCRdhi cells, (c) TCRdlo cells, and (d) TCRbþ cells of CD45þ cells. FACS analysis of dermal
cell suspensions isolated from mice treated or not with IMQ at indicated time points, showing the percentage of (e) macrophages (F4/80þ) of CD45þ cells, (f)
infiltrating monocytes (Ly6Chi) of CD11bþ cells within the CD45þ population, and (g) neutrophils (Ly6Ghi Ly6Cþ) cells of CD11bþ cells within the CD45þ
population. Quantification of the number of (h) total mast cells and (i) degranulated mast cells per microscopic field (MF) at indicated time points and
treatments. MHC, major histocompatibility complex. TCR, T cell receptor.
N Amberg et al.
Effects of Imiquimod on Hair Follicle Stem CellsCloser analysis with known stem cell markers for the Bu
(a6 Integrinhi CD34þ), IFE (a6 Integrinþ Sca-Ihi), and IF (a6
Integrinþ Lrig1þ) by flow cytometry (FACS) analysis at late
telogen revealed increased percentages of Ki67þ cells within
each of these cell compartments in IMQ-treated mice
(Figure 2feh, see Supplementary Figure S1feh). Taken
together, these results demonstrate that IMQ treatment has
different effects on the HFSC compartment depending on the
hair cycle stage, in particular, leading to increased stem cell
proliferation and premature entry into anagen when applied
at mid and late telogen.
Effects of IMQ treatment on the skin immune cell
composition during hair cycle
Because topical IMQ treatment also leads to a prominent
infiltration of immune cells into the skin, we next analyzed
the composition of the cutaneous inflammatory infiltrate
during the four hair cycle stages. FACS analysis of epidermal
cell suspensions (Supplementary Figure S2a online) revealed a
comparable activation of keratinocytes by IMQ at all stages,
as defined by MHC-II expression in CD45 cells (seeSupplementary Figure S2c). There was also a trend toward an
increase in the total number of immune cells (CD45þ) in
IMQ-treated epidermis at each time point (see Supplementary
Figure S2d). Interestingly, the relative number of MHC-IIþ
immune cells in the epidermis of untreated mice, which are
mainly LCs, was lower in mid telogen and anagen and
increased when IMQ was applied in mid and late telogen, as
well as anagen (Figure 3a). In contrast, in untreated skin, the
percentage of DETC (TCRdhi) was significantly higher in mid
telogen and anagen (Figure 3b). IMQ treatment decreased the
numbers of TCRdhi cells irrespective of the time of application
(Figure 3b). However, after IMQ treatment, the number of
TCRdlo gd T cells, the majority of which are most likely
infiltrating from the periphery, significantly increased at all
stages (Figure 3c). We were also able to detect TCRbþ cells in
the epidermis, which were highest during late telogen and
decreased after IMQ treatment (Figure 3d). FACS analysis of
dermal cell suspensions (see Supplementary Figure S2b)
showed that the percentages of CD45þ cells fluctuated be-
tween the distinct hair cycle stages, with significantly more
leukocytes in the dermis of untreated anagen mice, whichwww.jidonline.org 2143
Figure 4. Imiquimod (IMQ) treatment leads to infiltration of inflammatory
gd T cells and macrophages. FACS analysis of (a) epidermal and (b, c) dermal
cell suspensions isolated from mice treated or not with IMQ at late telogen,
showing the percentage of (a) TCRbþ cells of CD45þ cells, Vg3þ cells of
TCRdhi cells, and Vg3þ cells and Vg2þ cells of TCRdlo cells; (b) TCRbþ cells
of CD45þ cells, TCRdþ cells of CD45þ cells and Vg3þ cells, and Vg2þ cells
of TCRdþ cells; (c) F4/80þ CD11bþ cells of CD45þ cells, CD64þ MHC-IIlo
cells of CD45þ cells, F4/80þ CD11bþ cells of CD64þ MHC-IIlo cells, and
Ly6Cþ GR1 cells of F4/80þ CD11bþ cells. MHC, major histocompatibility
complex. TCR, T cell receptor.
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2144decreased after IMQ application (see Supplementary
Figure S2e). Closer inspection of the CD45þ cell compart-
ment revealed remarkable differences in macrophages (F4/
80þ CD11c), monocytes (CD11bþ Ly6Chi), and neutrophils
(CD11bþ Ly6Ghi Ly6Cþ) (Figure 3eeg). In line with a previous
report (Castellana et al., 2014), in untreated skin macrophage
ratios decreased from early to late telogen, thus allowing
anagen transition (Figure 3e). A similar trend was observed for
neutrophils and monocytes (Figure 3f and g). Importantly,
IMQ treatment during mid and late telogen and anagen, but
not in early telogen, induced infiltration of macrophages,
neutrophils, and monocytes (Figure 3eeg).
We next quantified mast cells using Giemsa staining,
because they express toll-like receptor 7 and were shown to
be implicated in topical IMQ response (see Supplementary
Figure S2f) (Heib et al., 2007). Total number of mast cells
did not change after IMQ treatment during early telogen and
mast cells were also not activated, as evidenced by the
number of degranulated mast cells (Figure 3h and i).Journal of Investigative Dermatology (2016), Volume 136However, when IMQ was applied during mid and late
telogen as well as anagen, the number of mast cells and their
activation state significantly increased. This effect was
strongest after IMQ application during anagen (Figure 3h
and i).
These results demonstrate that except for mast cells, which
remain constant during the whole hair cycle, in untreated
skin, all other myeloid cells (macrophages, neutrophils, and
monocytes) decrease during the transition from early to late
telogen and increase again in anagen. Moreover, except for
TCRdlo gd T cells, IMQ treatment had no significant effects on
the composition of the immune infiltrate of the skin when
applied during early telogen. In contrast, during all other hair
cycle stages, IMQ application significantly increased the
number of all myeloid cells including mast cells and TCRdlo
gd T cells, whereas the numbers of other T-cell populations in
the epidermis decreased.
IMQ treatment leads to infiltration of inflammatory gd T
cells and macrophages
Because T cells had been shown to play a crucial role in
IMQ-mediated skin inflammation (Pantelyushin et al., 2012),
and declining macrophage numbers were shown to favor
anagen induction (Castellana et al., 2014), we sought to
characterize both cell populations in more detail.
Within the epidermal T-cell populations, we detected
TCRbþ cells in untreated mice, which decreased on IMQ-
induced skin inflammation (Figure 4a, see Supplementary
Figure S3a online). These epidermal TCRbþ cells are pre-
dominantly memory T cells, as shown by expression of
CD8a, CD69, and CD103 (Supplementary Figure S3b)
(Heath and Carbone, 2013). Detailed investigation of the
epidermal gd T-cell population showed that TCRdhi express-
ing cells were exclusively DETC, as demonstrated by
expression of Vg3 (Figure 4a, see Supplementary Figure S3a),
whereas TCRdlo expressing cells were both DETC and infil-
trating Vg2þ T cells (Figure 4a, see Supplementary
Figure S3a, nomenclature according to Garman et al.,
1986). In the dermis, TCRbþ cell numbers did not signifi-
cantly change after IMQ application; however, gd T-cell
populations did, as reported previously (Figure 4b, see
Supplementary Figure S3c) (Pantelyushin et al., 2012).
Whereas in untreated mice, the majority of dermal gd T cells
expressed Vg3, on IMQ treatment we detected a strong
infiltrate of Vg2þ T cells that have recently been shown to be
key mediators of IMQ-induced psoriasiform skin inflamma-
tion (Figure 4b, see Supplementary Figure S3c) (Gray et al.,
2013).
In the dermis of IMQ-treated mice, we found an increased
percentage of F4/80þ CD11bþ cells, which are mainly
macrophages. Dendritic cells could be excluded from this
population by staining for CD64þMHC-IIlo cells, which were
increased after IMQ treatment and mainly consisted of F4/
80þ CD11bþ macrophages (Figure 4c and Supplementary
Figure S3d). Importantly, we detected an increase of Ly6Cþ
Gr1 cells within the macrophage population (F4/80þ
CD11bþ) in IMQ-treated skin, providing evidence that the
increase in dermal macrophages may be derived from infil-
trating monocytes rather than proliferation of skin-resident
macrophages (Figure 4c).
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Figure 5. Macrophages, but not T
cells, appear to regulate hair follicle
stem cell (HFSC) activity. (a) Stainings
for b4 integrin (green), Ki67 (red), and
nuclei (blue) from mice of indicated
genotypes and treatments. (b)
Quantification of anagen hair follicle
(HF) from mice of indicated genotypes
and treatments. FACS analysis
showing (c) CD45þ cells of live
epidermal cells (d), CD45þ cells of
live dermal cells, and (e) F4/80þ cells
of live dermal cells. (f) Stainings for b4
integrin (green), Ki67 (red), and nuclei
(blue). (g) Quantification of anagen HF
from Rag2/ mice of indicated
treatments. (h) Dermal FACS analysis
showing F4/80þ cells of CD45þ cells.
(i) Stainings for F4/80 (green), keratin 5
(red), and nuclei (blue) from mice of
indicated genotypes and treatments.
(j) Quantification of macrophage
numbers per microscopic field (MF)
from mice of indicated genotypes and
treatments. All scale bars 100 mm.
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We next investigated which immune cells might be causative
for IMQ-induced anagen induction. To investigate the role of
T cells in IMQ-induced anagen induction, we treated T- and
B-cell-deficient Rag2/ mice (see Supplementary Figure S4a
online) with IMQ during late telogen and monitored hair
cycle entry by Ki67 staining (Figure 5a). Surprisingly, in IMQ-
treated Rag2/ mice, only 40% of HFs were in anagen,
which was significantly lower than what was observed in
control Rag2þ/ HF, where 90% of HFs had entered anagen
(similar to what was observed with C57BL/6 in
Supplementary Figure S1e) (Figure 5b). To our surprise, FACS
analysis of immune cells from epidermal and dermal cell
suspensions (Figure 5cee) revealed that—when compared
with Rag2þ/ mice—untreated Rag2/ mice displayed
already elevated numbers of F4/80þ cells in the dermis with a
tendency to increase further after IMQ treatment (Figure 5e
and i). This finding led us to speculate whether the high
number of macrophages might prevent efficient anagen entry
after IMQ treatment. We therefore depleted skin-resident
macrophages by subcutaneous clodronate liposome injec-
tion (Supplementary Figure S4b) at late telogen. In wild-typemice, this resulted in anagen induction in almost 100% of all
HFs (see Supplementary Figure S4cee), similar to what was
observed in a previous report (Castellana et al., 2014).
Moreover, no changes in epidermal and dermal CD45þ im-
mune cell numbers could be seen (see Supplementary
Figure S4f and g). Interestingly, macrophage depletion fully
restored the capacity of Rag2/ HF to enter anagen
(Figure 5fej). Immunofluorescence staining for F4/80
revealed a broad distribution of the high number of F4/80þ
cells within the dermis of Rag2/ mice, which was restored
to control levels after chlodronate treatment (Figure 5i and j).
These data suggest that in the absence of T and B cells
increased numbers of dermal macrophages are present in the
dermis, which prevent efficient anagen entry after IMQ
treatment.
IMQ treatment shifts the balance of HFSC inhibitory and
activating factors
In search of a possible mechanism by which IMQ regulates
HF activity, we analyzed the expression of candidate growth
factors known to be activating (e.g., Wnt3a and Wnt7b) or
inhibiting (e.g., Bmp4) anagen entry (Castellana et al., 2014;www.jidonline.org 2145
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Figure 6. Imiquimod (IMQ) treatment shifts the balance of hair follicle stem cell (HFSC) inhibitory and activating factors. qRT-PCR data obtained from whole
skin lysates of mice of indicated time points and treatments, showing results for (a) Bmp4, (b) Wnt3a, (c) Wnt7b, (d) Ccl2, and (e) TNFa. Bmp4, bone
morphogenetic protein-4; qRT-PCR, quantitative real-time reverse transcription-PCR; TNFa, tumor necrosis factor-a; CCL2, chemokine (C-C Motif) ligand 2;
Wnt, wingless-related integration site; Tbp, TATA binding protein.
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2146Kandyba et al., 2013; Plikus et al., 2008). Quantitative real-
time reverse transcription-PCR analysis performed on total
skin lysates revealed that IMQ treatment leads to an increase
in Bmp4 expression during early telogen, but to reduced
Bmp4 levels during late telogen. Also macrophage depletion
during late telogen by clodronate treatment decreased Bmp4
expression levels similar to what was observed after IMQ
application (Figure 6a), showing that downregulation of
inhibitory factors is required for anagen entry. Interestingly,
the levels of Wnt3a and Wnt7b, which similar to a previous
report (Castellana et al., 2014) were found to be increased
after clodronate treatment, were not upregulated by IMQ
(Figure 6b and c). To our surprise, these factors significantly
decreased after IMQ treatment in late telogen, suggesting that
IMQ-induced anagen occurs by a different mechanism that
does not require Wnt upregulation.
Therefore, we looked at the expression of inflammatory
cytokines such as CCL2 and TNFa that had previously been
reported to be involved in precocious anagen induction after
injury (Chen et al., 2015). Both these cytokines were barely
detectable in the skin of untreated mice, and upregulated
after IMQ treatment during late telogen, but not during early
telogen (Figure 6d and e). These data suggest that after IMQ
treatment infiltrating macrophages produce proinflammatory
cytokines that stimulate HFSC activation.DISCUSSION
Most experiments with topical IMQ are performed in mice
aged 6e12 weeks. This time window covers different hair
cycle stages: early telogen (7e8 weeks), mid telogen (8e9
weeks), late telogen (9e10 weeks), and anagen (10e11
weeks), which might differently affect the response to IMQ.
Our data suggest that the composition of the immune
infiltrate and the activation state of different epidermal
stem cells changes according to the different hair cycle
stages. We show activation of stem cells located in the
2HG when IMQ is applied during mid and late telogen
with rapid anagen induction. As telogen can be divided
into a refractory (when hair is not responsive to activating
cues) and competent (when hair is responsive) phase
(Plikus et al., 2008), with refractory telogen lastingJournal of Investigative Dermatology (2016), Volume 136approximately 28 days, it is intriguing that IMQ can over-
come refractivity of telogen during the second hair cycle
and initiate anagen.
Previous studies reported that besides the dermal papilla,
dermal fibroblasts and adipocytes as well as skin-resident
dermal macrophages can produce important factors such as
Bmp4, Wnt3a, and Wnt7b, which regulate HFSC activity
(Castellana et al., 2014; Fuchs, 2007; Plikus et al., 2008).
Moreover, dermal resident macrophages were shown to
express IL-10 under a steady-state condition, thus playing an
anti-inflammatory and scavenging role in the skin
(Tamoutounour et al., 2013). However, under inflammatory
conditions, monocyte-derived macrophages infiltrate the skin
and support the production of cytokines such as TNFa, IL-6,
IL-12, and IFNs (Chen et al., 2015; Drobits et al., 2012;
Morimura et al., 2016; Terhorst et al., 2015). Injury-
induced CCL2 production by the skin was recently shown
to induce macrophage infiltration and TNFa production,
ultimately resulting in hair cycle induction (Chen et al.,
2015). Such macrophages have been shown to be derived
from Ly6Cþ cells from the blood (Willenborg et al., 2012). In
line with this, we can demonstrate CCL2 and TNFa pro-
duction in mice treated with IMQ during late telogen, which
is accompanied by macrophage influx, thus providing evi-
dence that also in the IMQ model, inflammatory macro-
phages favor hair cycle entry by production of cytokines.
Interestingly, depletion of skin-resident macrophages using
clodronate during the steady-state also leads to precocious
anagen induction, which might seem paradoxical. However,
it needs to be emphasized that steady-state resident macro-
phages analyzed in the clodronate experiment are very
different from infiltrating inflammatory macrophages, which
differentiate from circulating monocytes. These two cell
populations most likely have different functions, and it is
therefore not surprising that they secrete a different repertoire
of cytokines.
We find that in both conditions (clodronate depletion and
IMQ treatment) precocious anagen induction is accompa-
nied by reduced expression of Bmp4, a growth factor that has
been shown to inhibit the telogen-anagen transition and
anagen progression (Botchkarev, 2001). However, we did not
find increased levels of Wnt3a and Wnt7b in IMQ-treated
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clodronate depletion of resident macrophages. It is possible
that activated macrophages infiltrating the skin after IMQ
treatment might be able to activate HFSC by a Wnt-
independent mechanism. However, it is important to note
that we performed our expression analysis in total skin
lysates. Therefore, we cannot formally exclude that around
the HF there is a local increase of Wnt concentration.
Moreover, IMQ-induced infiltration of macrophages and
other immune cells leads to a cytokine storm able of acti-
vating HFSC, which might be associated with the dilution of
Wnt mRNA derived from resident macrophages. Recent
studies have shown that Wnt3a mediates anti-inflammatory
effects leading to reduced TNFa and IL-6 levels (Neumann
et al., 2010; Schaale et al., 2011). These observations sup-
port our results, which demonstrate that in early telogen
Wnt3a levels are unchanged with no monocytic infiltration,
whereas in late telogen Wnt3a is reduced and monocyte
influx as well as TNFa levels increased.
CCL2-induced monocyte recruitment and production of
TNFa does not seem to happen in early telogen, when high
numbers of resident macrophages are present in the dermis
already under physiological conditions possibly preventing
significant entry of infiltrating macrophages after IMQ treat-
ment. High macrophage numbers are seen in T-cell-deficient
Rag2/ mice already under steady-state conditions and are
maintained after IMQ treatment, thus providing an explana-
tion why IMQ-induced anagen is reduced. Only clodronate-
mediated depletion of resident macrophages leads to full
activation of HFSCs and anagen induction further supporting
the conclusion that resident macrophages inhibit whereas
inflammatory infiltrating macrophages stimulate anagen
induction.
Because our results show remarkable differences in the
response of the skin to IMQ treatment between different hair
cycle stages, experiments using IMQ should be performed
during a defined time window. We recommend applying
topical IMQ on murine back skin during mid and late tel-
ogen, as significant differences in both HFSC activation and
immune cell infiltration can be observed at this stage of the
hair cycle. This standardization would allow a better com-
parison of experiments performed in different laboratories.
MATERIAL AND METHODS
Mice
C57BL/6 and Rag2/ mice were purchased from Jackson Labora-
tories and kept in a conventional animal facility of the Medical
University of Vienna for several generations in accordance with
institutional policies and federal guidelines. Animal experiments
were approved by the Animal Experimental Ethics Committee of the
Medical University of Vienna and the Austrian Federal Ministry of
Science and Research.
Imiquimod treatment
Female and male mice were anesthetized and hair of the back skin
was shaved with an electrical small animal razor (Aesculap Favorita
II, #GT104, Aesculap, Maria Enzersdorf, Austria) 1 day before
starting IMQ (Aldara, Medapharma, Solna, Sweden) treatment for 7
days. Visual inspection of the shaved back skins was performed to
confirm the hair cycle stage of the mice. For telogen experiments,dark pigmentation and associated signs of hair regrowth on the back
skin led to exclusion of the respective mice; for anagen experiments,
the absence of dark pigmentation on the back skin led to exclusion
of the respective mice, according to Plikus et al. (2008). Around 30
mg of Aldara per mouse was used: 1 day after the last IMQ appli-
cation mice were killed and their back skin was analyzed.
Macrophage depletion
Anesthetized mice were shaved on their back skin at P63 and 50 ml
of liposomes either packed with phosphate buffered saline or
clodronate (Encapsula Nanosciences, Brentwood, TN) were injected
subcutaneously in the anterior and posterior dorsum. Liposomes
were a generous gift of Luigi Tortola. Liposome injection was
repeated every other day. At P65, IMQ was topically applied to the
back skin for 7 consecutive days. One day after the last IMQ
application, mice were killed and back skin was analyzed.
Histology
Paraffin sections and cryosections were prepared as previously
described (Amberg et al., 2015). Briefly, 4-mm paraffin sections were
stained with hematoxylin and eosin (Sigma-Aldrich, Vienna, Austria)
or Giemsa (Merck, Vienna, Austria) according to standard pro-
cedures. Six-micrometer frozen sections were subjected to immu-
nofluorescence stainings, using 4% paraformaldehyde (PFA) (Merck)
fixation for 10 minutes, followed by blocking with 1% BSA (Sigma),
5% Horse Serum (Life Technologies, Darmstadt, Germany), and
0.1% Triton X-100 (Merck) in phosphate buffered saline (Sigma).
Antibodies were diluted in blocking buffer and incubated over night
at 4 C. Sections were incubated with secondary antibodies (Life
Technologies, 1:500) and Hoechst (Sigma, 1 mg/ml) for 1 hour at
room temperature and mounted (DAKO, Vienna, Austria). Anti-
bodies employed are listed in Supplementary Table S1 online.
Epidermal thickness and IF length were measured from hema-
toxylin and eosin stained sections by taking at least 10 photographs
per sample with a 20 objective at a Nikon eclipse i80 microscope.
From each image, epidermal thickness was measured in three
different areas. Mast cell quantification was performed from Giemsa
stainings by taking at least 10 photographs per sample with a 20
objective. Both epidermal thickness measurement and mast cell
counting were performed using Adobe Photoshop PS5.
Flow cytometry
For immune cell analysis, dermal and epidermal cell suspensions
were isolated according to previous publications (Glitzner et al.,
2014; Holcmann et al., 2009). After separating epidermis and
dermis, cell suspensions were filtered and stained with fluorescently
labeled antibodies after blocking with Fc-block (BD Pharmingen,
Schwechat, Austria). Antibodies are listed in Supplementary
Table S1.
For Ki67 analysis, epidermal cell suspensions were isolated by
incubating the back skin dermal side down on 0.25 mg/ml ther-
molysin (thermolysin powder, Sigma, dissolved in DMEM) over night
(O.N.) at 4 C. Next day, epidermis was gently peeled of and
minced. Cell suspensions were filtered and stained with fluo-
rescently labeled antibodies after blocking with Fc-block (BD
Pharmingen, Schwechat, Austria). For intracellular staining, we first
used Zombie Aqua fixable dead cell staining dye (BioLegend, San
Diego, CA) according to the manufacturer’s instructions and then
followed the fixation and permeabilization protocol of the BD BrdU
flow kit (BD Biosciences), and finally 5 ml of Ki67 antibody was
added to each sample for 30 minutes at 4 C. All antibodies arewww.jidonline.org 2147
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flow cytometer (BD Biosciences) and analyzed using FlowJo
(Treestar, Ashland, OR).
Quantitative real-time reverse transcription-PCR
A piece of back skin was surgically removed from the anterior part of
the shaved back skin part, added to a tube containing 200 ml of
RNALater (Applied Biosystems, Foster City, CA), snap frozen in
liquid nitrogen, and stored at 80 C until further use. For RNA
isolation, skin was transferred to a Precellys tube (Peqlab, Erlangen,
Germany) containing 1 ml of trizol (Sigma) and homogenized using
a Precellys 24 homogenizer (Peqlab) at 2e3 cycles for 2 minutes.
RNA was extracted following the standard protocol for chloroform/
isopropanol precipitation. One hundred micrograms of RNA were
used for reverse transcription, using M-MuLV reverse transcriptase
(New England Biolabs, Ipswich, MA) and random hexamers (Invi-
trogen, Carlsbad, CA). cDNA was stored at 20 C until further use.
Quantitative real-time reverse transcription-PCR was run with SYBR
green (Peqlab) on an ABI7500 quantitative real-time reverse
transcription-PCR machine (Applied Biosystems). Data were calcu-
lated relatively to expression of reference gene Tbp. Primer se-
quences were ordered from MWG Eurofins (Ebersberg, Germany)
and can be found in Supplementary Table S2 online.
Statistical analysis
Data were analyzed by two-tailed Student’s t test. Error bars repre-
sent SD of at least two pooled independent experiments, unless
otherwise stated. P values less than 0.05 were considered statisti-
cally significant. *P < 0.05, **P < 0.005, ***P < 0.001.
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